Personalised medicine and fibrosis-targeting treatments are key growth areas. The global liver disease treatment market is ...

Altimmune said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease. The drug, pemvidutide, showed a ...

According to the latest study from BCC Research, the "Liver Disease Treatments: The Global Market" is projected to increase from $46.0 billion in 2024 to $69.1 billion by the end of 2030, at a ...

ABC News' Dr. Tara Narula breaks down the condition affecting nearly one in four Americans and the promising treatment giving patients new hope.

Medscape Education is a proud sponsor of the inaugural 2025 Cholestatic Liver Disease Summit, taking place June 26–28 in ...

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis ...

Altimmune shares rose 13% in premarket trading following an announcement it would present topline 24-week data from its Phase 2b trial evaluating pemvidutide as a treatment for those with metabolic ...

Hepatocellular carcinoma (HCC), the most common type of liver cancer and the third-leading cause of cancer-related deaths ...

This new review article highlights the critical role of ribosome biogenesis in liver health and disease progression.

Discover a study that found that individuals with higher baseline IL-1β levels experienced greater improvements in liver ...

One of the challenges with liver disease is that it can be a silent threat. In its early stages, it may cause only vague ...